A fat-reducing composition and its preparation method and application

Abstract

The present invention discloses a fat-reducing composition, a preparation method thereof, and an application thereof, wherein the fat-reducing composition comprises a seabuckthorn leaf extract and a first mixed component and / or a second mixed component; wherein the first mixed component comprises a vine tea extract and a monk fruit extract, and the second mixed component comprises a first freeze-dried coffee powder and a second freeze-dried coffee powder, wherein the second freeze-dried coffee powder contains chlorogenic acid. The preparation method of the fat-reducing composition of the present invention comprises mixing the components. The fat-reducing composition provided by the present invention has a better fat-reducing effect produced by the synergistic synergy of the components, and all of them are safe and have no side effects, do not cause dependence, and can reduce fat more effectively.

Description

Technical Field

[0001] The present invention relates to the technical field of health food, and in particular to a fat-reducing composition, a preparation method thereof, and an application thereof. Background Art

[0002] Obesity can generally be divided into simple obesity and secondary obesity. Simple obesity refers to a condition in which calorie intake exceeds calorie expenditure, resulting in excessive fat accumulation and abnormal weight. Simple obesity is the most common type of obesity, accounting for over 95% of all obesity cases.

[0003] Body mass index (BMI) is often calculated based on height and weight to reflect overall obesity: BMI = weight (kg) / height 2 (m 2 The "Guidelines for the Prevention and Control of Overweight and Obesity in Chinese Adults" define BMI as 18.5 ≤ BMI < 24 as normal; 24 ≤ BMI < 28 as overweight; and ≥ 28 as obese.

[0004] According to the latest report "Diabetes, Obesity and Metabolism", in 2023, the proportion of overweight people in my country was 34.8%, and the proportion of obese people was 14.1%.

[0005] Obesity is not only an independent disease, but also a risk factor for type 2 diabetes, cardiovascular disease, hypertension, stroke and multiple cancers. It is one of the top ten risk factors that lead to disease burden.

[0006] Existing weight loss products on the market primarily consist of medications and health supplements. While medications can reduce fat, they are highly addictive, have significant side effects, and can easily lead to weight rebound after discontinuation. Health supplements have a weaker fat-reducing effect, and some products use laxatives to reduce weight, which can be harmful to health. They also contain anthraquinones, which are highly addictive and have side effects.

[0007] Obese people are in urgent need of safe, effective and non-addictive fat-reduction products. Summary of the Invention

[0008] The technical problem to be solved by the present invention is to provide a fat-reducing composition, a preparation method thereof, and an application thereof, wherein the fat-reducing composition is safe, effective, and non-dependent, and is suitable for use in the preparation of fat-reducing products. Moreover, the preparation method of the fat-reducing composition is simple and convenient for industrial application.

[0009] To solve the above technical problems, the first aspect of the present invention is to provide a fat-reducing composition comprising a seabuckthorn leaf extract; and

[0010] a first mixing component and / or a second mixing component;

[0011] The first mixed component includes tea extract and monk fruit extract, the second mixed component includes a first freeze-dried coffee powder and a second freeze-dried coffee powder, and the second freeze-dried coffee powder contains chlorogenic acid.

[0012] In the fat-reducing composition provided herein, seabuckthorn leaves are the leaves of Hippophae rhamnoides L., a plant belonging to the genus Hippophae of the family Elaeagnaceae. Seabuckthorn leaf extract primarily comprises polyphenolic compounds, which can reduce abdominal fat. Rhizoma Cistanche extract primarily comprises flavonoids such as dihydromyricetin, which can improve glucose and lipid metabolism and insulin resistance. Momordica grosvenori extract contains mogroside V, which can reduce weight and lower blood lipids and is highly safe. Chlorogenic acid in the second freeze-dried coffee powder can reduce lipid synthesis and downregulate the expression of inflammatory factors, also lowering blood sugar. The first freeze-dried coffee powder primarily serves as a carrier. The fat-reducing composition formed by mixing the seabuckthorn leaf extract with the first mixed component (Rhizoma Cistanche extract and Momordica grosvenori extract), or the seabuckthorn leaf extract with the second mixed component (the first freeze-dried coffee powder and the second freeze-dried coffee powder), or the seabuckthorn leaf extract with the first mixed component and the second mixed component, exhibits a synergistic fat-reducing effect. Furthermore, each component in the present invention is safe, has no side effects, and is non-addictive.

[0013] It should be noted that the caffeine content in the first freeze-dried coffee powder and the second freeze-dried coffee powder in the present invention may be the same or different. Preferably, the caffeine content in the first freeze-dried coffee powder is higher than that in the second freeze-dried coffee powder, so as to provide coffee aroma and taste. For example, the caffeine content in the first freeze-dried coffee powder may be 3.97wt%, and the caffeine content in the second freeze-dried coffee powder may be 2.07wt%. In addition, it should be noted that although studies have shown that caffeine can increase fat metabolism and reduce the levels of free fatty acids and glycerol in the blood to a certain extent, its usage needs to reach 425mg / d and be combined with an energy-restricted diet to be effective. After the human body consumes a large amount of caffeine, it may cause side effects such as palpitations and headaches in people who are intolerant to caffeine. When the fat-reducing composition provided by the present invention is used to prepare a fat-reducing product, the caffeine content in each serving of the fat-reducing product (daily dosage) is less than 80mg to avoid adverse effects on people who are intolerant to caffeine.

[0014] Specifically, the fat-reducing composition comprises, by mass:

[0015] 2 to 12 parts by weight or 2 parts by weight or 8 parts by weight or 12 parts by weight, preferably 8 parts by weight, of seabuckthorn leaf extract, wherein the content of polyphenol compounds is not less than 20 wt% or not less than 25 wt%, preferably not less than 25 wt%;

[0016] 1 to 13 parts by weight or 1 part by weight or 4 parts by weight or 13 parts by weight, preferably 4 parts by weight, of a Tengcha extract, wherein the dihydromyricetin content is not less than 30 wt% or not less than 40 wt%, preferably not less than 40 wt%;

[0017] 1 to 4 parts by mass or 1 part by mass or 3 parts by mass or 4 parts by mass, preferably 4 parts by mass, of the Momordica grosvenori extract, wherein the content of mogroside V is not less than 1 wt% or not less than 1.5 wt%, preferably not less than 1.5 wt%.

[0018] Specifically, the fat-reducing composition comprises, by mass:

[0019] 2 to 12 parts by weight or 2 parts by weight or 8 parts by weight or 12 parts by weight, preferably 8 parts by weight, of seabuckthorn leaf extract, wherein the content of polyphenol compounds is not less than 20 wt% or not less than 25 wt%, preferably not less than 25 wt%;

[0020] 9 to 33 parts by mass, or 9 parts by mass, or 26 parts by mass, or 33 parts by mass, preferably 26 parts by mass, of first freeze-dried coffee powder;

[0021] The second freeze-dried coffee powder comprises 11 to 35 parts by mass, or 11 parts by mass, or 18 parts by mass, or 35 parts by mass, preferably 18 parts by mass, and has a chlorogenic acid content of 10 wt% to 15 wt% or 10 wt% to 12 wt% or 12 wt% to 15 wt% or 12 wt%, preferably 12 wt%.

[0022] Specifically, the fat-reducing composition comprises, by mass:

[0023] 2 to 12 parts by weight or 2 parts by weight or 8 parts by weight or 12 parts by weight, preferably 8 parts by weight, of seabuckthorn leaf extract, wherein the content of polyphenol compounds is not less than 20 wt% or not less than 25 wt%, preferably not less than 25 wt%;

[0024] 1 to 13 parts by weight or 1 part by weight or 4 parts by weight or 13 parts by weight, preferably 4 parts by weight, of a Tengcha extract, wherein the dihydromyricetin content is not less than 30 wt% or not less than 40 wt%, preferably not less than 40 wt%;

[0025] 1-4 parts by weight, or 1 part by weight, or 3 parts by weight, or 4 parts by weight, preferably 4 parts by weight, of a Momordica grosvenori extract, wherein the content of mogroside V is not less than 1 wt % or not less than 1.5 wt %, preferably not less than 1.5 wt %;

[0026] 9 to 33 parts by mass, or 9 parts by mass, or 26 parts by mass, or 33 parts by mass, preferably 26 parts by mass, of first freeze-dried coffee powder;

[0027] The second freeze-dried coffee powder comprises 11 to 35 parts by mass, or 11 parts by mass, or 18 parts by mass, or 35 parts by mass, preferably 18 parts by mass, and has a chlorogenic acid content of 10 wt% to 15 wt% or 10 wt% to 12 wt% or 12 wt% to 15 wt% or 12 wt%, preferably 12 wt%.

[0028] In the present invention, when the components in the fat-reducing composition are in preferred parts by weight, the synergistic effect between the components is most obvious, which can significantly reduce body weight, BMI, waist circumference, hip circumference and body fat percentage (P < 0.05), and subcutaneous fat thickness (P < 0.05), and the SF-36 score is significantly increased by 2.53% (P < 0.05), and the ZWQOL score is significantly reduced by 17.86% (P < 0.01).

[0029] Specifically, the seabuckthorn leaf extract is obtained by the following method:

[0030] S1. Seabuckthorn leaf pretreatment: crush the seabuckthorn leaves and sieve them for later use;

[0031] S2. Preparation of extract: adding pure water to the sea buckthorn leaves pre-treated in step S1, wherein the mass of the added pure water is 10 to 20 times the mass of the sea buckthorn leaves, heating the mixed system to 70°C to 95°C, stirring for 30 to 100 minutes, and filtering the liquid through a 50-200 mesh sieve to obtain an extract;

[0032] S3, post-treatment of the extract: centrifuge the extract obtained in step S2 at 2000-5000 rpm for 2-20 min, collect the clarified liquid, and concentrate the clarified liquid at 20-80°C and 40-70 mbar to a Brix value of 9-12%, and then perform UHT sterilization to obtain a concentrated extract;

[0033] S4, spray drying: spray drying the concentrated extract obtained in step S3 at an inlet temperature of 155-185° C. and an outlet temperature of 80-90° C. to obtain a powdered seabuckthorn leaf extract.

[0034] In the present invention, in step S1, the sea buckthorn leaves are crushed and sieved to a mesh size of, for example, 30 mesh or 40 mesh, which facilitates extraction while helping to reduce dust loss and equipment clogging risks during processing; in addition, the drying of the concentrated extract is not limited to the spray drying method. The purpose of the present invention, which preferably sprays and dries the sea buckthorn leaf extract, is to directly pulverize the sea buckthorn leaf extract, which has high production efficiency and good particle uniformity, and is convenient for subsequent applications.

[0035] To address the above technical issues, the second aspect of the present invention is to provide a use of the aforementioned fat-reducing composition in the preparation of a fat-reducing product. It is understood that, due to the synergistic effects of the fat-reducing composition provided by the present invention, it significantly reduces body weight, BMI, waist circumference, hip circumference, body fat percentage (P < 0.05), and subcutaneous fat thickness (P < 0.05), and significantly increases SF-36 scores by 2.53% (P < 0.05) and significantly decreases ZWQOL scores by 17.86% (P < 0.01). Therefore, the fat-reducing product prepared by using the composition in the preparation of a fat-reducing product exhibits at least all the beneficial effects of the fat-reducing composition. It should be noted that the fat-reducing product of the present invention includes oral liquids, granules, powders, capsules, or tablets.

[0036] To address the above technical issues, a third aspect of the present invention provides a method for preparing the aforementioned fat-reducing composition, wherein the components of the fat-reducing composition are uniformly mixed to obtain the fat-reducing composition. For example, a first mixed component is obtained by first powdering a vine tea extract and a monk fruit extract and mixing them in a desired proportion. Then, a first freeze-dried coffee powder and a second freeze-dried coffee powder are powdered and mixed in a desired proportion to obtain a second mixed component. Finally, as needed, a seabuckthorn leaf extract is powdered and mixed with the first mixed component and / or the second mixed component in a desired proportion. In the present invention, the mixing can be performed, for example, by stirring in a mixing tank.

[0037] In the present invention, the method for preparing the sea buckthorn leaf extract comprises extracting the sea buckthorn leaf extract from the sea buckthorn leaves using pure water as a solvent, and then spray drying to obtain the powdered sea buckthorn leaf extract; specifically, for example, the sea buckthorn leaves are first crushed and passed through a 30-mesh sieve (or a 40-mesh sieve), and then pure water 10 to 20 times the mass of the sea buckthorn leaf powder is added, and the mixture is heated to 70 to 95° C. and stirred for 30 to 100 minutes. The effluent is passed through a 50-200 mesh sieve, and then centrifuged at a speed of 2000 to 5000 rpm for 2 to 20 minutes, and the clarified liquid is collected. The clarified liquid is concentrated at 20 to 80° C. and a pressure of 40 to 70 mbar to a Brix of 9 to 12%, and the concentrated extract is spray dried at an inlet temperature of 155 to 185° C. and an outlet temperature of 80 to 90° C. to obtain the powdered sea buckthorn leaf extract.

[0038] In the present invention, the first freeze-dried coffee powder and the powdered second freeze-dried coffee powder can be prepared, for example, by purchasing commercially available first freeze-dried coffee powder and second freeze-dried coffee powder, mixing them in a desired proportion, and then grinding them. The mixture is then passed through a 30-mesh sieve (or a 40-mesh sieve) to reduce the particle size to facilitate mixing. Preferably, the seabuckthorn leaf extract, the vine tea extract, the monk fruit extract, the first freeze-dried coffee powder, and the second freeze-dried coffee powder are all powders.

[0039] In the present invention, the vine tea extract and the powdered Momordica grosvenori extract are both commercially available, or can be used after being passed through a 30-mesh sieve (or a 40-mesh sieve).

[0040] The fat-reducing composition of the present invention is intended to be mixed uniformly. During stirring, the order in which the materials are added does not constitute a limitation of the present invention. The method for preparing the fat-reducing composition of the present invention is simple to operate and is convenient for large-scale and industrial application. DETAILED DESCRIPTION

[0041] The following is a clear and complete description of the technical solutions of the present invention. Obviously, the embodiments described are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative efforts are within the scope of protection of the present invention.

[0042] Example 1 Preparation of fat-reducing composition

[0043] 1. Material preparation

[0044] 1) Preparation of powdered sea buckthorn leaf extract

[0045] S1. Seabuckthorn leaf pretreatment: crush the seabuckthorn leaves and pass through a 30-mesh sieve for later use;

[0046] S2. Preparation of extract: Add 14 times the mass of pure water to the crushed sea buckthorn leaves after pre-treatment in step S1, heat to 95°C, stir for 60 minutes, and pass the liquid through an 80-mesh sieve to obtain an extract;

[0047] S3, post-treatment of the extract: centrifuge the extract obtained in step S2 at 4000 rpm for 5 minutes, collect the clarified liquid, concentrate the clarified liquid at 55°C and 50 mbar until the Brix value reaches 10%, and then perform UHT sterilization to obtain a concentrated extract;

[0048] S4, spray drying: the concentrated and sterilized extract obtained in step S3 is added to a spray drying device, the inlet temperature is set to 175° C., the outlet temperature is set to 80° C., and the powdered sea buckthorn leaf extract is obtained by spray drying.

[0049] 2) Powdered vine tea extract (dihydromyricetin content: 40 wt%) and powdered Momordica grosvenori extract (mogroside V content: 1.5 wt%) were purchased from Hualuyuan Biotechnology Co., Ltd. and used directly.

[0050] 3) Preparation of a powdered mixture of the first freeze-dried coffee powder and the second freeze-dried coffee powder

[0051] The first freeze-dried coffee powder and the second freeze-dried coffee powder, which are commercially available and commissioned by Shanghai Touchuang Network Technology Co., Ltd., are taken. The chlorogenic acid content of the second freeze-dried coffee powder is 12 wt %. The first freeze-dried coffee powder and the second freeze-dried coffee powder are mixed in proportion, added to a grinder, and crushed. The mixture is sieved through a 40-mesh sieve to obtain a powdery mixture of the first freeze-dried coffee powder and the second freeze-dried coffee powder.

[0052] 2. Preparation of fat-reducing composition

[0053] 1) Add the prepared seabuckthorn leaf extract, vine tea extract and monk fruit extract into a mixing tank in proportion and stir for 30 minutes.

[0054] 2) Place the powdered mixture of the first freeze-dried coffee powder and the second freeze-dried coffee powder into the mixing tank from step 1) and continue stirring for 30 minutes. After metal detection, remove the mixture and set aside.

[0055] The addition amount of each component of the sample prepared in this example is shown in Table 1.

[0056] Table 1

[0057]

[0058] Example 2 Evaluation of the efficacy of the fat-reducing composition on mice

[0059] Experimental animals: 6-week-old male C57BL / 6J mice;

[0060] Experimental methods: Mice were fed a high-fat diet containing 60 kcal% fat, D12492. After four weeks of high-fat modeling, mice with significant weight gain were screened and randomly divided into 13 groups, with 8 mice in each group, which were used as model groups, experimental groups 1-5, and control groups 1-7. During this period, another 8 mice were selected and fed a maintenance diet (without high-fat modeling) as a blank group. Afterwards, 14 groups of mice were raised normally for 8 weeks, among which the mice in experimental groups 3-5 were respectively given 455 mg / kg of the fat-reducing composition of experimental groups 3-5 in Example 1 per day, the mice in experimental group 1 were given 394 mg / kg of the mixture of experimental group 1 in Example 1, the mice in experimental group 2 were given 121 mg / kg of the mixture of experimental group 2 in Example 1, the mice in control group 1 were given 61 mg / kg of the sea buckthorn leaf extract of control group 1 in Example 1 per day, the mice in control group 2 were given 30 mg / kg of the vine tea extract of control group 2 in Example 1 per day, the mice in control group 3 were given 30 mg / kg of the Momordica grosvenori extract of control group 3 in Example 1 per day, the mice in control group 4 were given 334 mg / kg of the mixture of control group 4 in Example 1 per day, the mice in control group 5 were given 364 mg / kg of the mixture of control group 5 in Example 1, the mice in control group 6 were given 364 mg / kg of the mixture of control group 6 in Example 1, and the mice in control group 7 were given 61 mg / kg of the mixture of control group 7 in Example 1. The model group and the blank group were administered an equal amount of the corresponding solvent (in this example, the solvent in both the experimental and control groups was normal saline. During feeding, the required amount of solid powder was diluted with normal saline and then provided to the mice for drinking). Body weights were measured weekly during the feeding period. After the feeding period, liver weight, abdominal fat weight, and subcutaneous fat weight were measured, and fasting blood glucose and insulin levels were measured. The HOMA-IR index was calculated, and the activities of fatty acid synthase (FAS) and carnitine palmitoyltransferase (CPT) in the liver were measured.

[0061] HOMA-IR index = fasting blood glucose level (mmol / L) × fasting insulin level (mIU / L) / 22.5; insulin units are converted as follows: 1ng / ml × 21.2 = μIU / ml (mIU / L);

[0062] In this embodiment, the synergistic effect q is calculated according to King's formula:

[0063]

[0064] Wherein, EA and EB are the effects of A and B acting alone, and E(A+B) is the effect of their combined use. When the q value is between 0.85 and 1.15, it is simply additive; when the q value is between 1.15 and 20, it is enhancing; when the q value is greater than 20, it is significantly enhancing; when the q value is between 0.56 and 0.85, it is antagonistic; and when the q value is less than 0.55, it is significantly antagonistic.

[0065] In this embodiment, for example, the use of a mixture of sea buckthorn leaf extract, vine tea extract and monk fruit extract is defined as EA acting alone, the use of a mixture of the first freeze-dried coffee powder and the second freeze-dried coffee powder is defined as EB acting alone, and the use of a fat-reducing composition formed by mixing the extract, vine tea extract, monk fruit extract, the first freeze-dried coffee powder and the second freeze-dried coffee powder is defined as E (A + B) in combination.

[0066] Test results

[0067] 1) The test results of weight changes of mice in each group are shown in Table 2-1 and Table 2-2, and the synergistic effect of weight loss among the groups is shown in Table 3:

[0068] Table 2-1

[0069]

[0070] Table 2-2

[0071]

[0072] In Tables 2-1 and 2-2, # indicates P < 0.05 compared with the blank group, ## indicates P < 0.01 compared with the blank group, * indicates P < 0.05 compared with the model group, and ** indicates P < 0.01 compared with the model group.

[0073] Table 3

[0074]

[0075] In Table 3, the numbers marked with * indicate P < 0.05 compared with the model group, and the numbers marked with ** indicate P < 0.01 compared with the model group.

[0076] From Tables 2-1 and 2-2, it can be seen that there was no significant difference in the initial body weight of the mice in each group (P < 0.05). Starting from the first week, the body weight of the mice in experimental groups 3 to 5 decreased significantly compared with the model group (P < 0.05), among which the mice in experimental group 5 lost the most weight. At the eighth week, the body weight of the mice in experimental group 5 decreased by 21.5%. The control group 1, experimental group 1 and experimental group 2 only began to show a weight loss effect from the third week; and the other control groups did not show a weight loss effect.

[0077] Experimental group 5 is equivalent to the combination of control group 4 and experimental group 2 or experimental group 1 and control group 7. The q values ​​calculated by King's formula are 1.36 and 1.40, respectively, which belong to the effect enhancement level. See Table 3 for details. Experimental group 1 consists of control groups 1 and 4, with a q value of 1.11. The sea buckthorn leaf extract powder is combined with the coffee mixed powder, and the weight loss effect is only simply additive. Control group 5 consists of control groups 2 and 4, and control group 6 consists of control groups 3 and 4. The above vine tea extract powder and monk fruit extract powder are used alone in combination with the coffee mixed powder, and no effect is improved. Control group 7 consists of control groups 2 and 3. The combination of vine tea and monk fruit also does not show an effect improvement. Experimental group 2 consists of control groups 1 and 7, with a q value of 1.16. The combination of sea buckthorn leaf extract, vine tea extract and monk fruit extract has a synergistic effect in inhibiting weight gain.

[0078] From the weight measurement of each group of mice, it can also be seen that the combination of sea buckthorn leaf extract, vine tea extract and monk fruit extract has a synergistic weight loss effect, or the synergistic weight loss effect of the combination of sea buckthorn leaf extract, vine tea extract and monk fruit extract, the first coffee freeze-dried powder and the second coffee freeze-dried powder is further enhanced, which is better than using the mixture of sea buckthorn leaf extract, vine tea extract and monk fruit extract alone, or better than using the mixture of the first coffee freeze-dried powder and the second coffee freeze-dried powder alone, or better than using sea buckthorn leaf extract alone, or better than using vine tea extract alone, or better than using monk fruit extract alone.

[0079] 2) The measurement results of liver weight, abdominal fat weight, and subcutaneous fat weight of mice in each group are shown in Table 4:

[0080] Table 4

[0081]

[0082] In Table 4, # indicates P < 0.05 compared with the blank group, ## indicates P < 0.01 compared with the blank group, * indicates P < 0.05 compared with the model group, and ** indicates P < 0.01 compared with the model group.

[0083] As shown in Table 4, compared with the blank group, the model group mice had significantly increased abdominal fat and subcutaneous fat weight (P < 0.01). Compared with the model group, experimental groups 1-5 all significantly reduced liver weight (P < 0.05). Experimental groups 1 to 5 and control group 1 also reduced abdominal fat and subcutaneous fat weight (P < 0.05). Experimental group 5 showed a greater effect in reducing abdominal and subcutaneous fat. The other control groups had no significant effect on reducing liver, abdominal fat, and subcutaneous fat weight (P > 0.05).

[0084] Through the calculation of the synergy coefficient, the calculation results of abdominal fat and subcutaneous fat are shown in Table 5 and Table 6 respectively:

[0085] Table 5

[0086]

[0087] Table 6

[0088]

[0089] In Tables 5 and 6, # indicates P < 0.05 compared with the blank group, ## indicates P < 0.01 compared with the blank group, * indicates P < 0.05 compared with the model group, and ** indicates P < 0.01 compared with the model group.

[0090] Table 5 shows that for reducing abdominal fat, Experimental Group 5 is equivalent to the combination of Control Group 4 and Experimental Group 2, or the combination of Experimental Group 1 and Control Group 7. Calculated using King's formula, the q values ​​were 1.44 and 1.49, respectively, placing them at the enhanced level of efficacy, indicating that these combinations can synergistically inhibit the increase in abdominal fat. Experimental Group 1, consisting of Control Groups 1 and 4, had a q value of 1.10. The combination of seabuckthorn leaf extract powder and coffee blend showed only additive weight loss efficacy. Control Group 5, consisting of Control Groups 2 and 4, and Control Group 6, consisting of Control Groups 3 and 4, showed no enhanced efficacy when either vine tea extract powder or monk fruit extract powder was combined with coffee blend. Control Group 7, consisting of Control Groups 2 and 3, had a q value of 1.22, indicating that the combination of vine tea and monk fruit synergistically inhibited abdominal fat. Experimental Group 2, consisting of Control Groups 1 and 7, had a q value of 1.17, indicating that the combination of seabuckthorn leaf extract, vine tea extract, and monk fruit extract synergistically inhibited the increase in abdominal fat.

[0091] Table 6 shows that for subcutaneous fat reduction, Experimental Group 5 is equivalent to the combination of Control Group 4 and Experimental Group 2, or the combination of Experimental Group 1 and Control Group 7. Calculated using King's formula, the q values ​​were 1.78 and 1.80, respectively, placing them at the enhanced level of efficacy, indicating that these combinations can synergistically inhibit subcutaneous fat gain. Experimental Group 1, consisting of Control Groups 1 and 4, had a q value of 1.28. Combining seabuckthorn leaf extract powder with coffee blend also synergistically enhanced the subcutaneous fat suppression effect. Control Group 5, consisting of Control Groups 2 and 4, and Control Group 6, consisting of Control Groups 3 and 4, showed no efficacy improvement when combining the above-mentioned vine tea extract powder and monk fruit extract powder with coffee blend, respectively. Control Group 7, consisting of Control Groups 2 and 3, had a q value of 1.01. The combination of vine tea and monk fruit powders simply added to the efficacy. Experimental Group 2, consisting of Control Groups 1 and 7, had a q value of 1.31. The combination of seabuckthorn leaf extract, vine tea extract, and monk fruit extract synergistically inhibited subcutaneous fat gain.

[0092] Combining Tables 5 and 6, it can be seen that the combined use of the seabuckthorn leaf extract, vine tea extract, and momordica grosvenori extract provided by the present invention is more effective than the use of the seabuckthorn leaf extract, vine tea extract, and momordica grosvenori extract alone. The combined use of the seabuckthorn leaf extract, vine tea extract, and momordica grosvenori extract, the first freeze-dried coffee powder, and the second freeze-dried coffee powder is more effective than the combined use of the seabuckthorn leaf extract, vine tea extract, and momordica grosvenori extract, and is also more effective than the combined use of the first freeze-dried coffee powder and the second freeze-dried coffee powder. The fat-reducing composition of the present invention produces a synergistically enhanced effect, with experimental group 5 having the best effect.

[0093] Furthermore, it was found that the combination of seabuckthorn leaf extract powder and coffee powder synergistically enhanced the subcutaneous fat suppression effect. This synergistic effect was not observed when combining vine tea extract, monk fruit extract, and coffee powder.

[0094] 3) The effects of fasting blood glucose, insulin and HOMA-IR (`X±S) on mice in each group are shown in Table 7:

[0095] Table 7

[0096]

[0097] In Table 7, # indicates P < 0.05 compared with the blank group, ## indicates P < 0.01 compared with the blank group, * indicates P < 0.05 compared with the model group, and ** indicates P < 0.01 compared with the model group.

[0098] As can be seen in Table 7, compared with the blank group, the model group had significantly increased fasting blood glucose (FBG), insulin, and HOMA-IR index (P < 0.01). Compared with the model group, experimental groups 2, 3, 5, and control group 1 were able to significantly reduce fasting blood glucose (FBG) (P < 0.05). Experimental groups 2 to 5, and control group 1 were able to significantly reduce insulin levels and HOMA-IR index (P < 0.05). Experimental group 5 had the best effect in reducing fasting blood glucose. The results showed that control group 4 had no significant effect on the fasting blood glucose, insulin, and HOMA-IR of mice. After consuming the fat-reducing composition provided by the present invention, it showed a significant effect of lowering blood glucose and alleviating insulin resistance.

[0099] 4) The results of the effects on the activities of fatty acid synthase FAS and carnitine palmitoyltransferase (CPT) in the liver of mice in each group (`X±S) are shown in Table 8:

[0100] Table 8

[0101]

[0102] In Table 8, # indicates P < 0.05 compared with the blank group, ## indicates P < 0.01 compared with the blank group, * indicates P < 0.05 compared with the model group, and ** indicates P < 0.01 compared with the model group.

[0103] As shown in Table 8, compared with the blank group, the CPT-1 activity in the model group was significantly reduced (P < 0.01), indicating that a high-fat diet impairs lipid transport and metabolism. Compared with the model group, experimental groups 1 to 5 and comparative example 1 all significantly increased CPT-1 activity (P < 0.05), indicating that the sea buckthorn leaf extract, the mixture of sea buckthorn leaf extract and coffee powder, the mixture of sea buckthorn leaf extract, vine tea extract, and monk fruit extract, and the fat-reducing composition of the present invention can increase the entry of fatty acyl CoA into mitochondria and promote fatty acid β-oxidation.

[0104] Table 8 also shows that compared to the blank group, the model group showed a significant increase in FAS activity (P < 0.01), suggesting that the high-fat diet induces increased activity of the lipid synthase FAS in the liver, promoting fat synthesis. Compared to the model group, experimental group 5 showed a significant decrease in FAS activity (P < 0.05). Experimental groups 1-4 and control groups 1 to 7 showed no significant effect. This suggests that the fat-reducing composition in experimental group 5 can reduce fat synthesis by reducing FAS activity.

[0105] This example shows that the fat-reducing composition provided by the present invention can significantly reduce the accumulation of fat in the liver, subcutaneous tissue, and abdomen, reduce fat volume, and can reduce fat synthesis (FAS), promote fatty acid transport and β-oxidation (CPT-1) to decompose fat, alleviate insulin resistance, and show excellent fat and weight reduction effects.

[0106] Example 3 Evaluation of the efficacy of the fat-reducing composition of experimental group 5 in a human food trial

[0107] Subject baseline information

[0108] Table 9 shows the 30 participants (7 males and 23 females) with a mean age of 38.73 ± 7.21 years and a mean BMI of 23.54 ± 3.67 kg / m 2 The subjects were overweight or not overweight but dissatisfied with their weight and body shape.

[0109] Table 9

[0110]

[0111] 2) Effects of the fat-reducing composition in experimental group 5 on the subjects' weight and BMI

[0112] Table 10 shows the effects of the fat-reducing composition of experimental group 5 on the weight and BMI of the subjects:

[0113] Table 10

[0114]

[0115] In Table 10, # indicates P < 0.05 compared with before taking; ## indicates P < 0.01 compared with before taking; * indicates P < 0.05 compared with the first month of taking; ** indicates P < 0.01 compared with the first month of taking;

[0116] Table 10 shows that after one and two months of using the fat-reducing composition in Experimental Group 5, both weight and BMI values ​​decreased significantly compared to pre-use weight (p<0.05). The change was calculated by subtracting the pre-use value from the post-use value. Compared to the change in the first month, the change in the second month was significantly greater. In the second month, weight decreased significantly by (1.11±1.33) kg (p<0.05), a decrease of 1.71%, and BMI decreased significantly by (0.34±0.47) kg / m 2 (p<0.05), a decrease of 1.45%.

[0117] 3) Effects of the fat-reducing composition in experimental group 5 on waist circumference, hip circumference, and waist-to-hip ratio (WHR) of subjects

[0118] Table 11 shows the effects of the fat-reducing composition of experimental group 5 on waist circumference, hip circumference and waist-to-hip ratio (WHR) of the subjects:

[0119] Table 11

[0120]

[0121] In Table 11, # indicates P < 0.05 compared with before taking the medicine; ## indicates P < 0.01 compared with before taking the medicine; * indicates P < 0.05 compared with the first month of taking the medicine; ** indicates P < 0.01 compared with the first month of taking the medicine.

[0122] Table 11 shows that after one and two months of using the fat-reducing composition in Experimental Group 5, waist circumference, hip circumference, and WHR values ​​all decreased significantly compared to pre-use measurements (p<0.05). Changes were calculated by subtracting the post-use values ​​from the pre-use values. Compared to the first-month decrease, the second-month decrease was even greater. None of these data were statistically significant. Waist circumference decreased by 2.16% in the first month and by 2.35% in the second month. This decrease, likely due to the significant decrease in the first month, did not significantly differ from the first-month change.

[0123] 4) Effect of the fat-reducing composition in experimental group 5 on the body fat percentage of the subjects

[0124] Table 12 shows the effects of the fat-reducing composition of experimental group 5 on the body fat percentage of the subjects

[0125] Table 12

[0126]

[0127] In Table 12, # indicates P < 0.05 compared with before taking the medicine; ## indicates P < 0.01 compared with before taking the medicine; * indicates P < 0.05 compared with the first month of taking the medicine; ** indicates P < 0.01 compared with the first month of taking the medicine.

[0128] Table 12 shows that compared to pre-use weight, body fat percentage decreased significantly after one and two months of using the fat-reducing composition in Experimental Group 5 (p < 0.05), but the difference was not statistically significant. In the first month, body fat percentage decreased by 3.71%. Compared to the change in the first month, body fat percentage decreased significantly in the second month by (2.12 ± 2.27)% (p < 0.05), a decrease of 6.34%. The rate of decrease in body fat percentage in the second month was faster.

[0129] 5) Effect of the fat-reducing composition of experimental group 5 on the thickness of subcutaneous fat in subjects

[0130] Table 13 shows the effects of the fat-reducing composition of experimental group 5 on the subcutaneous fat thickness at four points (point A, midpoint of the outer side of the arm at the lower edge of the right deltoid muscle, point B, right inferior angle of the scapula, point C, 3 cm from the right umbilicus, and point D, right anterior superior iliac spine) of subjects A, B, C, and D.

[0131] Table 13

[0132]

[0133] In Table 13, # indicates P < 0.05 compared with before taking the medicine; ## indicates P < 0.01 compared with before taking the medicine; * indicates P < 0.05 compared with the first month of taking the medicine; ** indicates P < 0.01 compared with the first month of taking the medicine.

[0134] As shown in Table 13, after one month of using the fat-reducing composition in Experimental Group 5, subcutaneous fat thickness at points A, B, C, and D was significantly reduced compared to pre-use (P < 0.05). After two months of using the fat-reducing composition in Experimental Group 5, subcutaneous fat thickness at points A, B, C, and D was significantly reduced (P < 0.05), with a 16.57% reduction at point D (P < 0.05). Example 3 was able to reduce subcutaneous fat thickness at all sites of the body, with a 16.57% reduction at point D (P < 0.05). This indicates that Example 3 significantly reduced subcutaneous fat thickness at the anterior superior iliac spine (ASIS) at point D.

[0135] Compared with the change in the first month, the change in the second month at point A at the lower edge of the right deltoid muscle was significantly reduced by (2.04±3.15) cm (p<0.05), a decrease of 10.23%. The second month reduced the growth rate of subcutaneous fat thickness.

[0136] 6) Effect of the fat-reducing composition in experimental group 5 on the quality of life of the subjects

[0137] Table 14 shows the effects of the fat-reducing composition of experimental group 5 on the quality of life of the subjects, and Table 15 shows the SF-36 score results:

[0138] Table 14

[0139]

[0140] Table 15

[0141]

[0142] In Tables 14 and 15, those marked with # indicate P < 0.05 compared with the results before administration; those marked with ## indicate P < 0.01 compared with the results before administration.

[0143] As shown in Table 14, one month after taking the fat-reducing composition in Experimental Group 5, both the ZWQOL and SF-36 scores showed an improvement compared to before treatment. After two months of treatment, the SF-36 score significantly increased by 2.53% (p<0.05), while the ZWQOL score significantly decreased by 17.86% (p<0.01). These results demonstrate that after two months of treatment, the composition improved the subjects' quality of life and reduced the impact of weight on their quality of life.

[0144] Table 15 shows that one month after taking the fat-reducing composition in Test Group 3, the SF-36 scores for physical function (RP) and general health (GH) significantly improved compared to pre-treatment (p<0.05). After two months of use, the SF-36 scores for physical function (PF), general health (GH), and health change (HT) all significantly increased (p<0.05). Both physical function (PF) and health change (HT) showed an improvement trend one month after use, with significant increases occurring in the second month.

[0145] It can be seen from this example that the fat-reducing composition provided by the present invention can effectively reduce body weight, BMI, waist circumference, hip circumference, as well as reduce body fat percentage and subcutaneous fat thickness, thereby improving the quality of life of the subjects.

[0146] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A fat-reducing composition, characterized in that: including sea buckthorn leaf extract; and a first mixing component and / or a second mixing component; The first mixed component includes a vine tea extract and a monk fruit extract, and the second mixed component includes a first freeze-dried coffee powder and a second freeze-dried coffee powder, wherein the second freeze-dried coffee powder contains chlorogenic acid; The seabuckthorn leaf extract is obtained by the following method: extracting the seabuckthorn leaf with pure water as a solvent, and then spray drying to obtain the seabuckthorn leaf extract in powder form, wherein the content of polyphenol compounds is not less than 20wt%; The dihydromyricetin content in the vine tea extract is not less than 30wt%; The content of mogroside V in the Momordica grosvenori extract is not less than 1 wt %; The content of chlorogenic acid in the second freeze-dried coffee powder is 10 wt % to 15 wt %.

2. The fat-reducing composition according to claim 1, wherein The fat-reducing composition comprises, in parts by mass: 2-12 parts by weight of seabuckthorn leaf extract; 1-13 parts by weight of Camellia oleifera extract; 1-4 parts by weight of Momordica grosvenori extract.

3. The fat-reducing composition according to claim 1, wherein The fat-reducing composition comprises, in parts by mass: 2-12 parts by weight of seabuckthorn leaf extract; 9 to 33 parts by weight of first freeze-dried coffee powder; 11 to 35 parts by mass of the second freeze-dried coffee powder.

4. The fat-reducing composition according to claim 1, wherein The fat-reducing composition comprises, in parts by mass: 2-12 parts by weight of seabuckthorn leaf extract; 1-13 parts by weight of Tengcha Tengcha extract; 1-4 parts by weight of Momordica grosvenori extract; 9 to 33 parts by weight of first freeze-dried coffee powder; 11 to 35 parts by mass of the second freeze-dried coffee powder.

5. The fat-reducing composition according to any one of claims 1 to 4, wherein The sea buckthorn leaf extract is 2 parts by weight, 8 parts by weight, or 12 parts by weight, and its polyphenol compound content is not less than 25 wt %.

6. The fat-reducing composition according to any one of claims 1, 2 or 4, wherein: 1 part by mass, 4 parts by mass, or 13 parts by mass of the Tengcha extract, wherein the dihydromyricetin content is not less than 40 wt%; The content of mogroside V in 1 part, 3 parts or 4 parts by mass of the Momordica grosvenori extract is not less than 1.5 wt %.

7. The fat-reducing composition according to any one of claims 1, 3 or 4, wherein: 9 parts by mass, 26 parts by mass, or 33 parts by mass of the first freeze-dried coffee powder; The second freeze-dried coffee powder contains 11 parts by mass, 18 parts by mass, or 35 parts by mass, and has a chlorogenic acid content of 10 wt % to 12 wt %.

8. The fat-reducing composition according to any one of claims 1, 3 or 4, wherein: The content of the chlorogenic acid in the second freeze-dried coffee powder is 12 wt % to 15 wt %.

9. The fat-reducing composition according to any one of claims 1, 3 or 4, wherein: The content of chlorogenic acid in the second freeze-dried coffee powder is 12 wt %.

10. The fat-reducing composition according to claim 1, wherein The seabuckthorn leaf extract is obtained by the following method: S1. Seabuckthorn leaf pretreatment: crush the seabuckthorn leaves and sieve them for later use; S2. Preparation of extract: adding pure water to the sea buckthorn leaves pre-treated in step S1, wherein the mass of the added pure water is 10 to 20 times the mass of the sea buckthorn leaves, heating the mixed system to 70°C to 95°C, stirring for 30 to 100 minutes, and filtering the liquid through a 50-200 mesh sieve to obtain an extract; S3, post-treatment of the extract: centrifuge the extract obtained in step S2 at 2000-5000 rpm for 2-20 min, collect the clarified liquid, and concentrate the clarified liquid at 20-80°C and 40-70 mbar to a Brix value of 9-12%, and then perform UHT sterilization to obtain a concentrated extract; S4, spray drying: spray drying the concentrated extract obtained in step S3 at an inlet temperature of 155-185° C. and an outlet temperature of 80-90° C. to obtain a powdered seabuckthorn leaf extract.

11. Use of the fat-reducing composition according to any one of claims 1 to 4 in the preparation of a fat-reducing product.

12. The use according to claim 11, characterized in that The fat-reducing product includes oral liquid, granules, powder, capsules or tablets.

13. A method for preparing the fat-reducing composition according to any one of claims 1 to 4, characterized in that: The fat-reducing composition is obtained by uniformly mixing the components of the fat-reducing composition.

Images